<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">877</article-id><article-id pub-id-type="doi">10.54101/ACEN.2023.1.5</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Salivary gland immunohistochemistry vs substantia nigra sonography: comparative analysis of diagnostic significance</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнительный анализ диагностической значимости иммуногистохимического исследования слюнной железы и ультразвукового исследования чёрной субстанции при болезни Паркинсона</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9441-4797</contrib-id><name-alternatives><name xml:lang="en"><surname>Khacheva</surname><given-names>Kristina K.</given-names></name><name xml:lang="ru"><surname>Хачева</surname><given-names>Кристина Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Neurologist, Research Assistant, Laboratory of Neuromorphology, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>врач-невролог, лаборант-исследователь лаб. нейроморфологии ФГБНУ НЦН</p></bio><email>christina.khacheva@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2174-2412</contrib-id><name-alternatives><name xml:lang="en"><surname>Karabanov</surname><given-names>Alexey  V.</given-names></name><name xml:lang="ru"><surname>Карабанов</surname><given-names>Алексей Вячеславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Neurologist, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>к.м.н., врач-невролог ФГБНУ НЦН</p></bio><email>doctor.karabanov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="spin">4439-3165</contrib-id><name-alternatives><name xml:lang="en"><surname>Bogdanov</surname><given-names>Rinat R.</given-names></name><name xml:lang="ru"><surname>Богданов</surname><given-names>Ринат Равилевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Professor, Department of neurology, M.F. Vladimirsky Moscow Regional Research and Clinical Institute</p></bio><bio xml:lang="ru"><p>д.м.н., доцент, профессор каф. неврологии факультета усовершенствования врачей ГБУЗ МО МОНИКИ им. М.Ф. Владимирского</p></bio><email>moniki-nevrol@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5222-5322</contrib-id><name-alternatives><name xml:lang="en"><surname>Voronkov</surname><given-names>Dmitry N.</given-names></name><name xml:lang="ru"><surname>Воронков</surname><given-names>Дмитрий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Senior Researcher, Laboratory of Neuromorphology, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>к.м.н., с.н.с. лаб. нейроморфологии ФГБНУ НЦН</p></bio><email>voronkovdm@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7704-1092</contrib-id><name-alternatives><name xml:lang="en"><surname>Sobolev</surname><given-names>Valery B.</given-names></name><name xml:lang="ru"><surname>Соболев</surname><given-names>Валерий Борисович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Neuromorphology, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>м.н.с. лаб. нейроморфологии ФГБНУ НЦН</p></bio><email>sobolevalera@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8726-8928</contrib-id><name-alternatives><name xml:lang="en"><surname>Chechetkin</surname><given-names>Andrey O.</given-names></name><name xml:lang="ru"><surname>Чечеткин</surname><given-names>Андрей Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Head, Laboratory of Ultrasound Studies, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>д.м.н., зав. лаб. ультразвуковых исследований ФГБНУ НЦН</p></bio><email>andreychechetkin@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4217-6736</contrib-id><name-alternatives><name xml:lang="en"><surname>Danilova</surname><given-names>Anastasiya D.</given-names></name><name xml:lang="ru"><surname>Данилова</surname><given-names>Анастасия Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Maxillo-Facial Surgeon, M.F. Vladimirsky Moscow Regional Research and Clinical Institute</p></bio><bio xml:lang="ru"><p>к.м.н., челюстно-лицевой хирург, с.н.с. отд. челюстно-лицевой хирургии ГБУЗ МО МОНИКИ им. М.Ф. Владимирского</p></bio><email>moniki-nevrol@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8287-741X</contrib-id><name-alternatives><name xml:lang="en"><surname>Sipkin</surname><given-names>Alexander M.</given-names></name><name xml:lang="ru"><surname>Сипкин</surname><given-names>Александр Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Leading Researcher, Head, Maxillo-Facial Surgery Department, M.F. Vladimirsky Moscow Regional Research and Clinical Institute</p></bio><bio xml:lang="ru"><p>д.м.н., в.н.с., рук. отд. челюстно-лицевой хирургии ГБУЗ МО МОНИКИ им. М.Ф. Владимирского</p></bio><email>moniki-nevrol@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2704-6282</contrib-id><name-alternatives><name xml:lang="en"><surname>Illarioshkin</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Иллариошкин</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., RAS Full Member, Director, Brain Institute, Deputy Director for Science, Research Center of Neurology</p></bio><bio xml:lang="ru"><p>академик РАН, д.м.н., профессор, директор Института мозга, зам. директора по научной работе ФГБНУ НЦН</p></bio><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">M.F. Vladimirsky Moscow Regional Research and Clinical Institute</institution></aff><aff><institution xml:lang="ru">ГБУЗ Московской области «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-03-29" publication-format="electronic"><day>29</day><month>03</month><year>2023</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>42</lpage><history><date date-type="received" iso-8601-date="2022-08-09"><day>09</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-22"><day>22</day><month>09</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Khacheva K.K., Karabanov A.V., Bogdanov R.R., Voronkov D.N., Sobolev V.B., Chechetkin A.O., Danilova A.D., Sipkin A.M., Illarioshkin S.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Хачева К.К., Карабанов А.В., Богданов Р.Р., Воронков Д.Н., Соболев В.Б., Чечеткин А.О., Данилова А.Д., Сипкин А.М., Иллариошкин С.Н.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Khacheva K.K., Karabanov A.V., Bogdanov R.R., Voronkov D.N., Sobolev V.B., Chechetkin A.O., Danilova A.D., Sipkin A.M., Illarioshkin S.N.</copyright-holder><copyright-holder xml:lang="ru">Хачева К.К., Карабанов А.В., Богданов Р.Р., Воронков Д.Н., Соболев В.Б., Чечеткин А.О., Данилова А.Д., Сипкин А.М., Иллариошкин С.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/877">https://annaly-nevrologii.com/pathID/article/view/877</self-uri><abstract xml:lang="en"><p><bold><italic>Introduction.</italic></bold> Parkinson's disease (PD) urges for new instrumental methods of diagnosis. Transcranial sonography of the substantia nigra (SN TCS) is an established method for early PD diagnosis but its application is limited. Recently, biopsies (primarily that of salivary gland) and test for abnormal α-synuclein are suggested to verify PD.</p> <p><bold><italic>Materials and methods.</italic></bold> We assessed 12 individuals with PD, Hoehn–Yahr 2.3 ± 0.4. The assessments included: UPDRS, NMSQ, NMSS, RBDSQ, PDQ-8, MoCA, and HADS scoring; SN TCS; and sublingual gland immunohistochemistry for phosphorylated α-synuclein (PS-129) with automated morphometric analysis.</p> <p><bold><italic>Results.</italic></bold> Substantia nigra hyperechogenicity was shown in 75% of patients whereas biopsy revealed PS-129 in 100% of patients. Echogenic area of the substantia nigra was 0.24 [0.21; 0.3] cm<sup>2</sup>. PS-129 inclusion area varied from 28.47 [27.55; 96.26] to 238.77 [234.13; 272.49] μm<sup>2</sup>, and PS-129 proportion varied from 13.4% to 93.4% of the nervous fiber area across the patients. We found relations between PS-129 and NMSQ (r = 0.8; p &lt; 0.001), NMSS (r = 0.9; p &lt; 0.001), PDQ-8 (r = 0.7; p = 0.003), UPDRS-I (r = 0.7; p = 0.009), UPDRS-II (r = 0.6; p = 0.03), and HADS (anxiety r = 0.8; p = 0.002; depression r = 0.6; p = 0.04) scores.</p> <p><bold><italic>Conclusion. </italic></bold>The results demonstrate a higher biopsy sensitivity as compared to SN TCS. Automated morphometric analysis has been newly applied to assess PS-129 occurrence. Immunohistochemistry results are directly related to non-motor symptom severity, which may indicate high probability of PS-129 presence and diagnosis confirmation in early disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение.</italic></bold> Существует необходимость в разработке новых методов инструментальной диагностики болезни Паркинсона (БП). Известным методом ранней диагностики БП является транскраниальная сонография черной субстанции (ТКС ЧС), однако она имеет ряд ограничений. В последние годы для верификации БП предложено прижизненное исследование биоптатов слюнной железы и других тканей на наличие патологических форм α-синуклеина.</p> <p><bold><italic>Материал и методы.</italic></bold> Обследованы 12 пациентов с БП, оценка по шкале Хён–Яра 2,3 ± 0,4. Всем пациентам проведены клиническая оценка по шкалам UPDRS, NMSQ, NMSS, RBDSQ, PDQ-8, MoCA, HADS; ТКС ЧС; иммуногистохимическое исследование биопсии подъязычной слюнной железы на наличие фосфорилированного α-синуклеина (ф-α-син) с автоматизированным морфометрическим анализом его распространённости.</p> <p><bold><italic>Результаты.</italic></bold> Гиперэхогенность ЧС отмечена у 75% пациентов, тогда как наличие ф-α-син по данным биопсии выявлено у 100% пациентов. Площадь эхогенного сигнала от ЧС составила 0,24 [0,21; 0,3] см<sup>2</sup>. Площадь включений ф-α-син составила от 28,47 [27,55; 96,26] до 238,77 [234,13; 272,49] мкм<sup>2</sup>, а доля ф-α-син относительно площади нервных волокон — от 13,4% до 93,4% у разных пациентов. Показана связь между долей ф-α-син и суммой баллов по NMSQ (r = 0,8; p &lt; 0,001), NMSS (r = 0,9; p &lt; 0,001), PDQ-8 (r = 0,7; p = 0,003), UPDRS-I (r = 0,7; p = 0,009), UPDRS-II (r = 0,6; p = 0,03), HADS (тревога r = 0,8; p = 0,002; депрессия r = 0,6; p = 0,04).</p> <p><bold><italic>Выводы. </italic></bold>Результаты свидетельствуют о более высокой чувствительности биопсийного метода по сравнению с ТКС ЧС. Впервые метод автоматизированного морфометрического анализа применён к оценке распространённости маркера БП ф-α-син. Результаты иммуногистохимического анализа прямо связаны с выраженностью немоторных симптомов, что позволяет предположить высокую вероятность выявления ф-α-син и подтверждения диагноза у пациентов на самых ранних стадиях заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Parkinson's disease</kwd><kwd>transcranial sonography</kwd><kwd>salivary gland biopsy</kwd><kwd>immunohistochemistry</kwd><kwd>α-synuclein</kwd><kwd>morphometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>транскраниальная сонография</kwd><kwd>биопсия слюнной железы</kwd><kwd>иммуногистохимия</kwd><kwd>α-синуклеин</kwd><kwd>морфометрия</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>19-15-00320</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Иллариошкин С.Н. Современные представления об этиологии болезни Паркинсона. Неврологический журнал. 2015; 20(4): 4–13. Illarioshkin S.N. Modern view on etiology of Parkinson’s disease. Neurological Journal. 2015; 20(4): 4–13. (In Russ.)</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Федотова Е.Ю., Чечеткин А.О., Иллариошкин С.Н. Возможности транскраниальной сонографии в диагностике экстрапирамидных заболеваний. Анналы клинической и экспериментальной неврологии. 2010; 4(4): 43–50. Fedotova E.Y., Chechetkin A.O., Illarioshkin S.N. Possibilities of transcranial sonography in extrapyramidal disorders. Annals of Clinical and Experimental Neurology. 2010; 4(4): 43–50. (In Russ.) doi: https://doi.org/10.17816/psaic322</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bjorklund G., Stejskal V., Urbina M.A. et al. Metals and Parkinson’s disease: mechanisms and biochemical processes. Curr. Med. Chem. 2018; 25(19): 2198–2214.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jeong S., Jang W., Shin D.W. Association of statin use with Parkinson’s disease: dose-response relationship. Mov. Disord. 2019; 34(7):1014–1021. doi: 10.1002/mds.27681</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Azizova T.V., Banikova M.V., Grigoryeva E.S. et al. Occupational exposure to chronic ionizing radiation increases risk of Parkinson’s disease incidence in Russian Mayak workers. Int. J. Epidemiol. 2020; 49(2): 435–447. doi: 10.1093/ije/dyz230</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Benassi B., Filomeni G., Montagna C. et al. Extremely low frequency magnetic field (ELF-MF) exposure sensitizes SH-SY5Y cells to the pro-Parkinson’s disease toxin MPP+. Mol. Neurobiol. 2016; 53(6): 4247–4260. doi: 10.1007/s12035-015-9354-4</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Avanipully J.N., Thekkekkara D., Sahyadri M. et al. The role of olfactory system in the etiogenesis of Parkinson’s diseases: an overview. J. Pharmacol. Pharmacother. 2022; 13(1): 31–39. doi: 10.1177/0976500X221085802</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Spillantini M.G., Goedert M. Synucleinopathies: past, present and future. Neuropathol. Appl. Neurobiol. 2016; 42(1): 3–5. doi: 10.1111/nan.12311</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Braak H., Del Tredici K., Rüb U. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 2003; 24(2): 197–211. doi: 10.1016/s0197-4580(02)00065-9</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Jellinger K.A. Synuclein deposition and non-motor symptoms in Parkinson disease. J. Neurol. Sci. 2011; 310(1–2): 107–111. doi: 10.1016/j.jns.2011.04.012</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Сальков В.Н., Воронков Д.Н., Хачева К.К. и др. Клинико-морфологический анализ случая болезни Паркинсона. Архив патологии. 2020; 82(2): 52–56. Sal’kov V.N., Voronkov D.N., Khacheva K.K. et al. Clinical and morphological analysis of a caseof Parkinson’s disease. Pathology Archive. 2020; 82(2): 52–56. (In Russ.) doi: 10.17116/patol20208202152</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015; 30(12): 1591–1601. doi: 10.1002/mds.26424</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Beach T.G., Adler C.H. Importance of low diagnostic accuracy for early Parkinson’s disease. Mov. Disord. 2018; 33(10): 1551–1554. doi: 10.1002/mds.27485</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Кравченко М.А., Чечеткин А.О. К вопросу об изучении природы ультразвукового феномена гиперэхогенности черной субстанции. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2019; (3): 15–20. Kravchenko M.A., Chechetkin A.O. On the question of studying the nature of the ultrasonic phenomenon of hyperechogenicity of the substantia nigra. Bulletin of the National Society for the Study of Parkinson’s Disease and Movement Disorders. 2019; (3): 15–20. (In Russ.) doi: 10.24411/2226-079Х-2019-12128</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mei Y.L., Yang J., Wu Z.R. et al. Transcranial sonography of the substantia nigra for the differential diagnosis of Parkinson’s disease and other movement disorders: a meta-analysis. Parkinsons Dis. 2021; 2021: 8891874. doi: 10.1155/2021/8891874</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Visanji N.P., Mollenhauer B., Beach T.G. et al. The systemic synuclein sampling study: toward a biomarker for Parkinson’s disease. Biomark. Med. 2017; 11(4): 359–368. doi: 10.2217/bmm-2016-0366</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Соболев В.Б., Худоерков Р.М Иммуногистохимическое выявление α-синуклеина в слюнной железе как биомаркер болезни Паркинсона. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2017; (2): 16–23. Sobolev V.B., Khudoyerkov R.M. Immunohistochemical detection of α-synucle-in in the salivary gland as a biomarker of Parkinson’s disease. Bulletin of the National Society for the Study of Parkinson’s Disease and Movement Disorders. 2017; (2): 16–23. (In Russ.)</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Pouclet H., Lebouvier T., Coron E. et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol. Dis. 2012; 45(1): 305–309. doi: 10.1016/j.nbd.2011.08.014</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Adler C.H., Dugger B.N., Hinni M.L. et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014; 82(10): 858–864. doi: 10.1212/WNL.0000000000000204</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sobolev V.B., Voronkov D.N., Khudoerkov R.M. Treatment of histological material for the detection phosphotylated and unphosphorilated apha-synuclein. Аsymmetry. 2016; 10(4): 77–84.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Гуменюк И.С., Чуприненко Л.М., Сотниченко А.С. и др. Автоматизированный морфометрический анализ как метод определения содержания компонентов внеклеточного матрикса и количественной оценки ядерных антигенов. Архив патологии. 2017; 79(5): 49–56. Gumenyuk I.S., Chuprinenko L.M., Sotnichenko A.S. et al. Automatic morphometric analysis as a method for determining the level of extracellular matrix components and for quantifying nuclear antigens. Pathology Archive. 2017; 79(5): 49–56. (In Russ.) doi: 10.17116/patol201779549-56</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Kalia L.V., Lang A.E., Hazrati L.N. et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015; 72(1): 100–105. doi: 10.1001/jamaneurol.2014.2704</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wang W., Song N., Jia F. et al. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson’s disease mouse model. Neurochem. Int. 2018; 114: 71–79. doi: 10.1016/j.neuint.2018.01.006</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jafari S., Etminan M., Aminzadeh F., Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov. Disord. 2013; 28(9): 1222–1229. doi: 10.1002/mds.25458</mixed-citation></ref></ref-list></back></article>
